Astellas boosts ocular pipeline with gene therapy acquisition
15-08-2018
Astellas accuses Cipla of infringing overactive bladder patent
07-06-2018
designer491 / iStockphoto.com
UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Crescendo Biologics, Zai Lab, Takeda, Astellas, collaboration, licensing agreement, psoriasis, biologics
